Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 4/20 | 0.54 |
| ▸ | EGFR | P00533 | 4/20 | 0.52 |
| ▸ | DCUN1D1 | Q96GG9 | 3/20 | 0.49 |
| ▸ | BTK | Q06187 | 2/20 | 0.46 |
| ▸ | UBE2M | P61081 | 2/20 | 0.44 |
| ▸ | KRAS | P01116 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.43 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.42 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.42 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21958713 | 0.85 | EGFR (0.66) | TEAD1EGFRDCUN1D1BTKKRAS | |
| SCHEMBL24781284 | 0.84 | SLC6A9 (0.52) | TEAD1EGFRDCUN1D1BTKKRAS | |
| SCHEMBL21958241 | 0.84 | TEAD1 (0.50) | TEAD1EGFRDCUN1D1BTKUBE2M | |
| SCHEMBL24780804 | 0.82 | TEAD1 (0.48) | TEAD1EGFRDCUN1D1BTKUBE2M | |
| SCHEMBL23592000 | 0.82 | TEAD1 (0.48) | TEAD1EGFRDCUN1D1BTKUBE2M | |
| SCHEMBL21958108 | 0.80 | SLC6A9 (0.56) | TEAD1EGFRDCUN1D1BTKGRIN2B | |
| SCHEMBL24780719 | 0.79 | TEAD1 (0.71) | TEAD1EGFRDCUN1D1BTKKMT2A | |
| SCHEMBL21957254 | 0.79 | TEAD1 (0.71) | TEAD1EGFRDCUN1D1BTKKMT2A | |
| SCHEMBL21958163 | 0.79 | TEAD1 (0.71) | TEAD1EGFRDCUN1D1BTKKMT2A | |
| SCHEMBL21958811 | 0.78 | SLC6A9 (0.46) | TEAD1EGFRDCUN1D1BTKGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-20220402869-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-22 | — | — | US | disclosed |
| WO-2021133896-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2020081572-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | TEAD1 1/4885EGFR 3966/4885DCUN1D1 2158/4885 |
| US-20220402869-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | TEAD1 1/4885EGFR 2755/4885DCUN1D1 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.